Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 7/20 | 0.34 |
| ▸ | KDR | P35968 | 6/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 2/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | CLK1 | P49759 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14850244 | 0.92 | GCGR (0.33) | RETKDRS1PR1 | |
| SCHEMBL17354286 | 0.89 | S1PR1 (0.33) | RETKDRS1PR1MAPT | |
| SCHEMBL14850242 | 0.85 | ALOX5AP (0.37) | RETKDRKIF11TP53MAPT | |
| SCHEMBL14850224 | 0.85 | RET (0.32) | RETKDRS1PR1ALOX5APFEN1 | |
| SCHEMBL14120 | 0.85 | DYRK1A (0.36) | RETKDRS1PR1EPHX2ALOX5AP | |
| SCHEMBL17354240 | 0.81 | S1PR1 (0.31) | S1PR1 | |
| SCHEMBL14850223 | 0.81 | C1R (0.34) | RETKDRS1PR1 | |
| SCHEMBL14853493 | 0.80 | HDAC11 (0.33) | — | |
| SCHEMBL14853447 | 0.79 | BDKRB1 (0.41) | S1PR1TP53MAPTPIM1DYRK1A | |
| SCHEMBL14850217 | 0.79 | CHEK1 (0.36) | RETKDRKIF11TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9845297-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9845297-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2016-02-04 | — | — | US | disclosed |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2016-02-04 | — | — | US | disclosed |
| US-9216979-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216979-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | RET 4806/4885KDR 4838/4885S1PR1 3139/4885 |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | RET 4806/4885KDR 4838/4885S1PR1 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.